Compare
Cabaletta Bio, Inc. vs Aura Biosciences, Inc. vs SAB Biotherapeutics, Inc. vs Sutro Biopharma, Inc.
| Latest fiscal year | Cabaletta Bio, Inc. CABA | Aura Biosciences, Inc. AURA | SAB Biotherapeutics, Inc. SABSRevenue covers only part of its income (partial revenue) | Sutro Biopharma, Inc. STRO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $102.48M |
| Revenue growth (YoY) | n/a | n/a | n/a | +65.2% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | -154.5% |
| Net margin | n/a | n/a | n/a | -186.5% |
| Net income | -$167.86M | -$106.19M | $13.27M | -$191.09M |
| EPS (Diluted) | -$2.10 | -$1.76 | -$0.79 | -$22.49 |
| Operating cash flow | -$131.08M | -$84.74M | -$44.78M | -$177.23M |
| Free cash flow | -$132.31M | -$85.19M | -$45.71M | n/a |
| Cash & equivalents | $82.98M | $59.52M | $10.50M | $58.13M |
| Total assets | $165.08M | $169.43M | $172.81M | $173.83M |
| Total liabilities | $53.03M | $32.52M | $21.32M | $306.28M |
| Shareholders' equity | $112.05M | $136.91M | $151.49M | -$132.45M |
| Return on year-end equity | -149.8% | -77.6% | 8.8% | n/a |
| Shares outstanding | 100.48M | 63.59M | 47.61M | 8.58M |
Revenue, most recent five fiscal years
| Fiscal year | Cabaletta Bio, Inc. | Aura Biosciences, Inc. | SAB Biotherapeutics, Inc. | Sutro Biopharma, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | n/a | $102.48M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | n/a | $62.04M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $153.73M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $67.77M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $61.88M Ended 2021-12-31 |